Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
Status:
Terminated
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in
patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab
or placebo. Each patient's participation will last approximately 1.5 years.